Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies.
A study from five hepatology units documenting 157 cases of drug-induced hepatitis and a second study from a laboratory of immunology which tested more than 100,000 sera permitted us to establish the frequency of antiorganelle antibodies and their diagnostic value in drug-induced hepatitis. In drug-induced hepatitis caused by a heterogenous group of drugs consisting of ajmaline, aminopterine, isaxonine, isoniazid, perhexiline, phenylbutazone and troleandromycine, antiorganelle antibodies were absent or rare. In drug-induced hepatitis caused by another heterogenous group of drugs, including clometacin, fenofibrate, oxyphenisatin and papaverine, antismooth muscle, antinucleus and antimitochondria antibodies were found in isolation or in different combinations in 70% of cases. From the presence of antismooth muscle antibodies in sera, we could trace 30 cases of clometacin-induced hepatitis. The third group included drug-induced hepatitis with special antibody:iproniazid-induced hepatitis with antimitochondrial antibody 6 and tienilic acid (ticrynafen)-induced hepatitis with antiliver/kidney microsome antibody 2 (anti-LKM2). These two antibodies are rare in routine sera and were absent in patients who received the drug and had no liver damage. From the presence of corresponding antibodies, we detected six cases of iproniazid-induced hepatitis and 67 cases of tienilic acid-induced hepatitis. Antiorganelle antibodies found in high titers disappeared in 2 to 24 months following withdrawal of the offending drug. The fourth group was represented by halothane-induced hepatitis; antiliver/kidney microsome antibody 1 was weak and infrequent. Similarities between drug-induced hepatitis of the second group and lupoïd hepatitis suggest that drugs may reveal this spontaneous disorder.(ABSTRACT TRUNCATED AT 250 WORDS)
D000818:Animals; D001323:Autoantibodies / Q000032:analysis*; D056486:Chemical and Drug Induced Liver Injury / Q000276:immunology*; D006221:Halothane / Q000009:adverse effects; D006801:Humans; D007210:Indoleacetic Acids / Q000009:adverse effects; D007490:Iproniazid / Q000009:adverse effects; D008099:Liver / Q000166:cytology / Q000276:immunology*; D008861:Microsomes / Q000276:immunology; D008862:Microsomes, Liver / Q000276:immunology; D008930:Mitochondria, Liver / Q000276:immunology; D009130:Muscle, Smooth / Q000276:immunology; D009940:Organoids / Q000276:immunology*; D051381:Rats; D013989:Ticrynafen / Q000009:adverse effects
D001323:Autoantibodies; D007210:Indoleacetic Acids; D007490:Iproniazid; D013989:Ticrynafen; C017136:clometacin; D006221:Halothane